Group 1 - The Hong Kong innovative drug sector experienced a downward trend, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 1% in early trading on February 26 [1] - Among the constituent stocks, Jiage Ankang-B led with a gain of over 5%, while Baiji Shenzhou fell sharply by 3% [1] - The industry is seeing active external licensing transactions, with Innovent Biologics and Eli Lilly forming a global strategic partnership focused on oncology and immunology [3] Group 2 - Key pipelines are making progress overseas, with two innovative drugs from CSPC Pharmaceutical Group starting Phase III clinical trials and receiving FDA IND approval [3] - Jianghai Securities predicts that by 2026, pharmaceutical business development (BD) transactions will focus on unmet clinical needs, technological differentiation, and globalization [3] - Huachuang Securities emphasizes the transition in the innovative drug industry from quantity to quality, suggesting a focus on differentiated domestic and international pipelines by 2025 [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with top ten weighted stocks including CSPC Pharmaceutical Group and Baiji Shenzhou [3]

隔夜全球资本市场迎来普涨行情，欧美股市全线走高，科技股成为上涨核心驱动力，贵金属、大宗商品同步异动。而美股盘后算力龙头英伟达发布的超预期 财报，更是进一步点燃市场情绪，成为当日全球市场的绝对焦点。 当地时间2月25日，美股三大指数全线收涨，连续两个交易日携手上行。Wind数据显示，截至收盘，道琼斯工业指数涨0.63%，报 49482.15点；纳斯达克指 数涨1.26%，报23152.08点；标普500指数涨0.81%，报6946.13点。欧洲市场同步走强，截至收盘，法国CAC40指数涨0.47%，英国富时100指数涨1.18%，德 国DAX指数涨0.76%。 | 美股指数 | | | | --- | --- | --- | | 道琼斯 | 纳斯达克 | 标普5( | | 49482.15 | 23152.08 | 6946. | | +307.65 +0.63% +288.40 +1.26% +56.06 + | | | | 中国金龙 | 纳指100期货 | 标普500 | | 7545.55 | 25344.25 | 6954 .! | | -35.49 -0.47% -37.75 -0.15% | | - ...

⑧伦敦基本金属全线上涨，LME期锡涨7.19%报53915.0美元/吨，LME期铝涨2.62%报3174.5美元/吨， LME期铅涨2.07%报1995.5美元/吨，LME期铜涨1.39%报13349.5美元/吨，LME期镍涨0.76%报18045.0美 元/吨，LME期锌涨0.22%报3387.0美元/吨； ⑨美债收益率集体上涨，2年期美债收益率涨3.10个基点报3.471%，3年期美债收益率涨3.06个基点报 3.486%，5年期美债收益率涨3.29个基点报3.622%，10年期美债收益率涨2.10个基点报4.052%，30年期 美债收益率涨1.94个基点报4.699%； ⑩欧债收益率涨跌不一，英国10年期国债收益率涨1.2个基点报4.316%，法国10年期国债收益率跌1.2个 基点报3.253%，德国10年期国债收益率涨0.1个基点报2.705%，意大利10年期国债收益率跌0.6个基点报 3.306%，西班牙10年期国债收益率跌0.9个基点报3.108%。 ④欧洲三大股指收盘全线上涨，德国DAX指数涨0.73%报25169.13点，法国CAC40指数涨0.4%报8553.11 点，英国富时100指数涨1 ...

美股开盘，三大指数高开。道指涨0.53%，纳指涨0.75%，标普500指数涨0.55%。 受英伟达和甲骨文股价上涨支撑，主要股指延续了前一交易日的涨势。市场关注英伟达、赛富时及Snowflake等公司即将公布的财报。 特斯拉涨2.31%，亚马逊涨1.04%，微软涨0.97%，苹果下跌0.11%，谷歌下跌0.21%。 | 名称 | 现价 | 涨跌巾一 | | --- | --- | --- | | 特斯拉(TESLA) | 418.840 | 2.31% | | TSLA.O | | | | 亚马逊(AMAZON) | 210.730 | 1.04% | | AMZN.O | | | | 微软(MICROSOFT) | 392.760 | 0.97% | | MSFT.O | | | | 英伟达(NVIDIA) | 194.640 | 0.93% | | NVDA.O | | | | 脸书(META PLAT ... | 644.620 | 0.83% | | META.O | | | | 苹果(APPLE) | 271.850 | -0.11% | | AAPL.O | | | | 谷歌(ALPHABET . ...

Group 1 - The Livermore Chinese concept stock index experienced a slight decline of 0.1% at the beginning of trading on February 25 [1] - Among the constituent stocks, BeiGene saw a drop of over 3% [1] - Tencent Music, Xpeng Motors, and NetEase each fell by more than 2% [1]

Group 1: Hillhouse Capital (HHLR) - Hillhouse Capital's HHLR fund reported a total market value of $3.104 billion at the end of Q4 2025, a decrease of 24% from the previous quarter, indicating a strategy of "focusing on core and shrinking edges" [2][4] - The top ten holdings include seven Chinese concept stocks, which account for nearly 90% of the total portfolio, primarily in internet e-commerce, biomedicine, and fintech sectors [2][4] - Significant increases in holdings were observed for Pinduoduo and Alibaba, with Pinduoduo's market value rising to $1.216 billion (up 24.77%) and Alibaba's to $795 million (up 65.07%) [3][4][5] - HHLR has reduced positions in competitive or non-core areas, clearing out stocks like Baidu and NetEase, while also entering positions in tech stocks like TSMC and Google [5] Group 2: Himalaya Capital - Himalaya Capital, managed by Li Lu, reported a Q4 2025 market value of $3.57 billion, up 10% from $3.23 billion in the previous quarter, maintaining a concentrated investment style [7][9] - The top four holdings (Google, Bank of America, Pinduoduo, and Berkshire Hathaway B) account for over 87% of the portfolio, with Google being the largest holding at $1.565 billion (43.86%) [9][10] - The fund exited its position in SOC and initiated a new position in Crocs, reflecting a focus on brands with strong market presence and cash flow [10] Group 3: Berkshire Hathaway - Berkshire Hathaway's Q4 2025 report, the last under CEO Warren Buffett, showed a portfolio dominated by familiar names, including Apple, American Express, and Coca-Cola [11][12] - Berkshire reduced its Apple holdings by over 10.29 million shares, marking the third consecutive quarter of reduction, while still maintaining Apple as its largest holding [13][14] - The company also significantly reduced its stake in Bank of America and Amazon, while increasing positions in Chevron and new investments in The New York Times, indicating a cautious approach to high-value assets [15][16] - Berkshire's cash reserves reached $381.7 billion, surpassing stock holdings for the fifth time in history, suggesting a strategic wait for better investment opportunities [16][18]

Group 1: Market Performance - The A-share biopharmaceutical ETF Huatai Fuhua (159839) rose by 1.1%, with a total trading volume exceeding 22 million yuan, marking the fourth consecutive day of inflows totaling over 20 million yuan [2] - The Hong Kong biopharmaceutical ETF Huatai Fuhua (513280) fluctuated and closed flat, with a trading volume exceeding 42 million yuan, and a net inflow of over 17 million yuan in the last 60 days [3] - The majority of the popular component stocks in the biopharmaceutical ETF Huatai Fuhua (159839) showed positive performance, with Changchun High-tech hitting the daily limit and its subsidiary GenSci141 ointment receiving clinical trial approval [5] Group 2: Company Performance - WuXi AppTec (药明康德) reported a significant performance increase, with a projected net profit growth of 41.3% in 2025, driven by the TIDES business, which saw revenue growth exceeding 90% [8] - WuXi Biologics (药明生物) achieved a record total of 945 projects, with a 30% growth in dual monoclonal antibodies and ADC projects, indicating strong future revenue potential [8] - The domestic clinical CRO market is expected to return to a growth trajectory in 2025, benefiting companies like Tigermed (泰格医药) from improved order prices and increased clinical pipeline numbers [8] Group 3: Industry Trends - The global CXO industry is expected to continue its strong recovery, with significant investment and transaction demand in the biotech and pharmaceutical sectors anticipated to rebound in 2025 [7] - The Chinese innovative drug market is showing robust activity, with a 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic market [7] - The Chinese innovative drug sector is transitioning from pipeline expectations to revenue realization, with over 70% of companies projected to achieve positive revenue growth in 2025 [11]

昨日（2月24日），港股科技方向走低。国证港股通科技指数(987008.SZ)下跌2.47%，该指数成分股 中，华虹半导体上涨超3%，小鹏汽车-W上涨超1%，百济神州上涨0.65%，瑞声科技上涨0.31%，同程 旅行下跌0.09%。 相关ETF方面，Wind数据显示，港股科技ETF天弘（159128）昨日全天成交额为1.06亿元，溢折率为 0.69%，盘中获净申购超8000万份。 资金流向方面，Wind数据显示，2月13日该ETF净流入额为6655.05万元，截至2月13日，已连续25个交 易日获资金净流入，累计净流入额为8.49亿元。该ETF最新流通份额为27.28亿份，最新流通规模为 24.32亿元。 港股科技ETF天弘（159128）紧密跟踪港股通科技指数，成分股均属于沪深港通标的，不受QDII额度 的限制，可T+0交易，该ETF还配备了场外基金联接A（024885）、联接C（024886）。 消息面上，据智通财经，全球最大AI开源社区Hugging Face公布新一期开源大模型榜单，阿里巴巴最新 开源的原生多模态模型千问3.5登顶全球榜首。在最新一期Hugging Face模型榜单前十中，有8款来自中 ...

研究报告 Research Report 25 Feb 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 跨国药企多次认可，创新转型成果凸显，平台价值值得期待 Multiple Recognitions from MNCs, Clear Progress in Innovation Transformation, Platform Value Highly Anticipated [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$10.06 目标价 HK$13.07 HTI ESG 3.0-2.5-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$115.92bn / US$14.82bn 日交易额 (3 个月均值) US$140.76mn 发行股票数目 11,522mn 自由流通股 (%) 68% 1 年股价最高最低值 HK ...

研究报告 Research Report 25 Feb 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 跨国药企多次认可，创新转型成果凸显，平台价值值得期待 Multiple Recognitions from MNCs, Clear Progress in Innovation Transformation, Platform Value Highly Anticipated [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$10.06 目标价 HK$13.07 HTI ESG 3.0-2.5-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$115.92bn / US$14.82bn 日交易额 (3 个月均值) US$140.76mn 发行股票数目 11,522mn 自由流通股 (%) 68% 1 年股价最高最低值 HK ...